— Know what they know.
Not Investment Advice

WST NYSE

West Pharmaceutical Services, Inc.
1W: +2.4% 1M: +6.0% 3M: +18.0% YTD: +44.2% 1Y: +34.0% 3Y: +10.2% 5Y: -3.6%
$398.29
+3.56 (+0.90%)
 
Weekly Expected Move ±2.9%
$370 $381 $392 $403 $415
NYSE · Healthcare · Medical - Instruments & Supplies · Tech Score Strong Buy · Power 71 · $28.0B mcap · 70M float · 0.940% daily turnover · Short 52% of daily vol
Credit Risk of going bust: lower than 93% of companies Debt: 1.1% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.34 (down 99.9%), West Pharmaceutical Services, Inc. would be worth roughly what it owes.
Total debt $312.1M against a stock market value of $27.78B.
Distance to default 16.41 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $166.5M (short-term plus half of long-term), stock volatility 31.4%; Altman Z 18.65. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Balance Sheet Trends

Total Assets
$4.3B +17.2% ▲
5Y CAGR: +8.9%
Total Liabilities
$1.1B +13.8% ▲
5Y CAGR: +3.1%
Shareholders Equity
$3.2B +18.4% ▲
5Y CAGR: +11.4%
Cash & Investments
$791M +63.3% ▲
5Y CAGR: +5.2%
Total Debt
$417M +36.5% ▲
5Y CAGR: +5.1%
Net Debt
-$375M -108.9% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$763M$894M$854M$485M$791M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$763M$894M$854M$485M$791M
Net Receivables$489M$507M$512M$552M$574M
Inventory$378M$415M$435M$377M$444M
Other Current Assets$112M$103M$136M$124M$169M
Total Current Assets$1.7B$1.9B$1.9B$1.5B$2.0B
Property, Plant & Equip.$1.1B$1.3B$1.5B$1.7B$0
Goodwill & Intangibles$133M$126M$124M$117M$118M
Long-Term Investments$208M$205M$210M$202M$212M
Other Non-Current Assets$56M$38M$21M$74M$2.0B
Total Non-Current Assets$1.6B$1.7B$1.9B$2.1B$2.3B
Total Assets$3.3B$3.6B$3.8B$3.6B$4.3B
— Liabilities —
Accounts Payable$232M$215M$242M$239M$254M
Short-Term Debt$44M$2M$134M$19M$23M
Deferred Revenue$49M$57M$42M$50M$0
Other Current Liabilities$45M$54M$54M$100M$214M
Total Current Liabilities$594M$519M$672M$550M$655M
Long-Term Debt$209M$207M$73M$203M$298M
Other Non-Current Liab.$108M$99M$107M$104M$22M
Total Non-Current Liabilities$384M$413M$277M$411M$439M
Total Liabilities$978M$932M$948M$961M$1.1B
— Equity —
Common Stock$19M$19M$19M$19M$19M
Retained Earnings$2.5B$3.0B$3.5B$4.0B$4.4B
Accumulated OCI-$160M-$183M-$144M-$258M-$106M
Total Stockholders Equity$2.3B$2.7B$2.9B$2.7B$3.2B
Total Liabilities & Equity$3.3B$3.6B$3.8B$3.6B$4.3B
— Key Metrics —
Total Debt$325M$318M$309M$305M$417M
Net Debt-$437M-$576M-$545M-$179M-$375M
Total Investments$208M$205M$210M$202M$212M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms